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Abstract 
Introduction: The objective of this study was to explore the frequency of red
cell alloantibodies and autoantibodies among β-thalassaemia patients who
received regular transfusions.
Material and methods: This study included 501 patients with β-thalassaemia.
This work planned to study the presence of alloantibodies and autoantibodies
to different red cell antigens in multitransfused thalassaemia patients using
the ID. Card micro typing system. 
Results: Of a total of 501 β-thalassaemia patients included in the study, 11.3%
of patients developed alloantibodies; 9.7% of these alloantibodies were clinically
significant. The most common alloantibodies were anti-K, anti-E and anti-C. The
rate of incidence of these alloantibodies was 3.9%, 3.3% and 1.7% respectively.
Autoantibodies occurred in 28.8% of the patients and 22.1% of these antibodies
were typed IgG. There was a significant association between splenectomy with
alloimmunization and autoantibody formation (p = 0.03, p = 0.001 respectively).
There was no significant association between alloantibody, autoantibody
formation and number of transfused packed red cells. 
Conclusions: Alloimmunization to minor erythrocyte antigens and erythrocyte
autoantibodies of variable clinical significance are frequent findings in transfused
β-thalassaemia patients. There is an association between absence of the spleen
and the presence of alloimmunization and autoantibody formation. 
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Introduction
Thalassaemia is among the most common genetic disorders worldwide,
particularly in the Mediterranean region, Africa, the Middle East and
Southeast Asia [1]. Thalassaemia is a hereditary anaemia resulting from
defects in haemoglobin production [2]. β-Thalassaemia, which is caused
by a decrease in the production of β globin chains, affects multiple 
organs and is associated with considerable morbidity and mortality [3].
Accordingly, lifelong care is required and financial expenditures for proper
treatment are substantial [4]. The recommended treatment for
thalassaemia major involves regular blood transfusions, usually
administered every 2 to 5 weeks to maintain a pre-transfusion
haemoglobin level above 9-10.5 g/dl. One of the complications of blood
transfusion is the formation of alloantibodies and autoantibodies against
red blood cell (RBC) antigens [5]. 
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Results from a number of studies have
demonstrated various frequencies and percentages
of alloantibody and autoantibody formation in
multi-transfused patients [6]. 
Some alloantibodies may cause haemolytic
transfusion reactions, which limits the possibility
of safe transfusion, while others are clinically
insignificant. Red cell autoantibodies appear less
frequently but can result in haemolysis and
difficulty in blood cross-matching [7]. 
Antibodies must be identified in the recipient’s
serum before each transfusion so that compatible
blood can be provided. The causes of allo  -
immunization in thalassaemia patients are not fully
understood. However, data suggest that the
recipient’s immune status, absence of spleen and
difference in the red cell phenotype between
donors and recipients are likely to contribute further
to the phenomenon [8].
The aim of this study was to explore the
frequency of alloimmunization and erythrocyte
autoantibodies among β-thalassaemia patients
receiving regular transfusions and the factors that
might contribute to their development, and to
investigate the RBC phenotype of Egyptians.
Material and methods
This study was conducted over a 2-year period
from January 2006 to December 2007 at the
Paediatric Haematology Unit of the National
Research Centre (NRC). The study was approved by
the Ethics Committee of the NRC. Written consent
was provided for each patient.
A total of 501 β-thalassaemia patients who
received regular blood transfusions were included
in the study. They were 389 patients with β-thalas  -
saemia major (228 males and 161 females) 
aged 2-24 years, 59 patients with β-thalassaemia
intermedia (24 males and 35 females) aged 
4-26 years and 53 patients with sickle cell-β-
  thalassaemia syndrome (27 males and 26 females)
aged 4-19 years.
The diagnosis of thalassaemia was confirmed by
standard haemoglobin electrophoresis and measure-
ments of Hb A, A2 and F. 
Clinical transfusion records of 501 β-thalas  -
saemia patients who fulfilled the criteria were
analysed for ethnic background; age at start of
transfusion and number of transfused packed red
cells (the majority of our patients had been exposed
to non-leukodepleted blood for a long time before
introduction of the universal leukodepletion protocol
for thalassaemia patients). All patients in our unit
received fully blood matched for only ABO and 
Rh (D) antigens. Presence of the spleen was also
recorded. There were no available data about the
time from start of transfusion to antibody
formation. Patients received supportive treatment
in the form of folic acid (5 mg/day, oral), calcium 
(40-80 mg/day, oral) and vitamin D (400 IU/day, oral).
Patients with connective tissue disease or
autoimmune disease, or receiving immuno  sup  -
pressive or immunomodulatory drugs were excluded
from the study.
Laboratory investigation
The practical part of this work aimed to study
the presence of alloantibodies and autoantibodies
to different red cell antigens in multitransfused
thalassaemia patients using the ID – Card micro
typing system (Gel tear, Switzerland). Dia Cell I, II
and III were used to screen for the presence of red
cell alloantibodies and the Dia Panel to identify
these alloantibodies.
All pre-transfused patients were routinely tested
for ABO and Rh D antigen. 
Screening of the sera for erythrocyte antibodies
and identification tests: the idea of this test was to
detect alloimmune antibodies formed against any
RBC antigen in the tested sera; this was done with
two different tests: screening and identification tests.
The antibody screening test was done with
a combination of 3 sets of commercial group O red
blood cells which have been typed for clinically
significant antigens as well as rare antigens. These
3 sets are known as Dia – cell I, II, III. 
Dia cell I contains the following antigens:
D, C, e, Cω, k, kpb, Jsb , Fya, JKb, Fyb, Leb, P, N, S, Lub
and xga.
Dia cell II contains the following antigens:
D, E, c, k, Kpb, Jsb, Fya, JKa, Leb, M, N, S, Lub and xga.
Dia cell III contains the following antigens: 
C, E, k, kpb, Jsa, Fyb, JKb, Lea, P, N, S, Lub and xga.
Positive sera (with Dia cell I or II or III or all) were
examined by an identification test using the Dia
panel, which consists of 11 different group O red
cells: k, C, E, JKb, Lea, kpa, M, I, Fyb, N, S.
Statistical analysis
Statistical Package for the Social Sciences (SPSS)
program version 9 was used for analysis of data.
Data were summarized as mean ± SD and
percentage.
Comparison of multiple subgroups was done
using one-way ANOVA.
Fisher’s Exact Test Calculator for a 2 × 2 con  -
tingency table was used.
Analysis of two independent variables was done
by using a non-parametric test (Mann-Whitney 
U test).
In all tests, the value of p was considered
significant if > 0.05.
Results
Characteristics of β-thalassaemia patients are
summarized in Table I. There was a highly signi  -
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ficant difference between and within the 3 groups
regarding age, start of transfusion and rate of
transfusion (p = 0.001). Also, Table I shows the
percentage of our patients that had splenectomy.
Table II demonstrates the frequency of red blood
cell alloantibody formation in β-thalassaemia
patients. Of the total 501 multi-transfused β-thalas  -
saemia patients 57 patients (11.3%) developed
alloantibodies. Forty-nine (9.7%) of these allo  -
antibodies were clinically significant (i.e. capable of
causing haemolytic transfusion reaction or
haemolytic disease of newborn). 
The most common alloantibodies were anti-K
(Kell system), anti-E and anti-C (Rhesus system).
The incidence of these alloantibodies was 20 (3.9%),
17 (3.3%) and 9 (1.7%) respectively of the total 501
patients with β-thalassaemia.
Furthermore, comparison between groups of 
β-thalassaemia patients revealed a highly
significant association between β-thalassaemia
major compared to sickle cell-β-thalassaemia
syndrome, and β-thalassaemia intermedia
compared to sickle cell-β-thalassaemia (p = 0.001)
regarding both the total of clinically significant
patients and total alloantibodies.
Table III demonstrates the frequency of red blood
cell autoantibodies in β-thalassaemia patients. 
This study revealed that 145 (28.8%) of the total
501 patients with β-thalassaemia had auto  -
antibodies, and 111 (22.1%) of them were typed
immunoglobulin G (IgG). Immunoglobulin G was
detected in 99 (25.4%) of 389 patients with 
β-thalassaemia major, 4 (6.7%) of 59 patients with
β-thalassaemia intermedia and 8 (15%) of 53
patients with sickle cell-β-thalassaemia syndrome.
Also, regarding total autoantibodies Table III
shows a highly significant association between
groups of β-thalassaemia major compared to 
β-thalassaemia intermedia, and β-thalassaemia
intermedia compared to sickle cell-β-thalassaemia
syndrome (p = 0.001, p = 0.04 res  pectively).  
Table IV represents the association of splen  -
ectomy with alloantibodies and autoantibodies 
in β-thalassaemia patients. Among the splene  -
ctomized group, 30 patients with β-thalas  saemia
major had alloantibodies and 123 patients with 
β-thalassaemia major had autoantibodies, while in
the non-splenectomized group none of them had
alloantibodies or auto  antibodies (p = 0.001).  
Overall, of the 233 β-thalassaemia patients with
splenectomy, 35 (15%) patients became alloim  -
munized and of the 269 patients without splene  -
ctomy, 22 patients (8.1%) became alloimmunized
(p = 0.03). Also, of the 233 patients with splene  -
ctomy, 140 patients (60%) developed auto  -
antibodies and of 269 patients without
splenectomy, 5 patients (1.8%) developed auto  -
antibodies (p = 0.001).
Analysis using the Mann-Whitney test shows
that there was no significant association between
alloantibody or autoantibody formation and the
number of transfused packed red cells (p = 0.5, 
p = 0.9 respectively). Also, there was no significant
association between alloantibody or autoantibody
formation and age at start of transfusion (p = 0.3,
p = 0.5 respectively) (Table V).
Discussion
Only a few studies in the world have investigated
the frequency and causes of alloimmunization and
autoimmunization [9]. In the present study we
examined these elements and defined the common
RBC phenotypes among Egyptians which have not
been previously described.
In this study the frequency of alloimmunization
was 11.3% in transfusion-dependent thalassaemia
patients. Previous data on presumed homogeneous
populations in Italy showed an overall low rate
(10%) of alloimmunization [10]. This is consistent
Items β-Thalassaemia  β-Thalassaemia Sickle cell-β Value
major (n = 389) intermedia (n = 59) thalassaemia (n = 53) of p
Age [years] (2–24)* (4–26)* (4–19)* 0.001
Mean ± SD 9.29 ±3.98 12.73 ±4.58 10.49 ±2.97
Start of transfusion (6–30)* (24–72)* (10–48)* 0.001
[months]
Mean ± SD 13.37 ±4.21 43.02 ±7.73 29.26 ±12.31
Rate of transfusion (4–12)* (3–12)* (2–12)* 0.001
[units/year]
Mean ± SD  9.43 ±2.41 5.05 ±1.58 6.46 ±2.19
Splenectomy:
• Yes 214 (55%) 11 (18.6%) 10 (18.9%)
• No 175 (45%) 48 (81.4%) 43 (81.1%)
*minimum to maximum, SD – standard deviation, p value < 0.05 is significant, p value < 0.01 is highly significant
Table I. Characteristics of β-thalassaemia patients
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with our study. Similarly, Ho et al. [7] in Hong Kong
found that the alloimmunization rate in thala  s  -
saemia patients was 7.4%. Other studies by Noor
Haslina et al. [8] and Karimi et al. [9] reported that
the incidence of alloimmunization in Malay and
Shiraz, Southern Iran, was 8.6% and 5.3%
respectively.
Our low alloimmunization rate in this study and
other similar studies can probably be explained by
the similarity in the ethnicity between patients and
donors. All of our alloimmunized patients were
Egyptian and most of our blood donors were also
Egyptian. In Hong Kong the majority of immunized
patients were Southern Chinese and all the blood
donors were predominantly of the same ethnic
origin. A lower rate of alloimmunization in their
study was explained by their access to phe  -
notypically matched donors in Hong Kong [7].
On the other hand, the alloimmunization rate 
in two studies done in Greece [11] and Kuwait [6] 
Table II. Frequency of red blood cell alloantibody formation in β-thalassaemia patients
Alloantibody β-Thalassaemia  β-Thalassaemia  Sickle cell-β Total Value
major (n = 389) intermedia (n = 59) thalassaemia (n = 53) (n = 501) of p
Anti-K* 14 (3.5%) 2 (3.3%) 4 (7.5%) 20 (3.9%) p1 = 1
p2 = 0.2
p3 = 0.4
Anti-C* 6 (1.5%) – 3 (5.6%) 9 (1.7%) p1 = 0.5
p2 = 0.08
p3 = 0.1
Anti-E* 8 (2%) 2 (3.3%) 7 (13.2%) 17 (3.3%) p1 = 0.6
p2 = 0.01
p3 = 0.09
Anti-Fya 2 (0.5%) – 4 (7.5%) 6 (1.2%) p1 = 1
p2 = 0.002
p3 = 0.05
Anti-M 1 (0.2%) – 1 (1.8%) 2 (0.4%) p1 = 1
p2 = 0.2
p3 = 0.2
Anti-Kpa* 2 (0.5%) – 1 (1.8%) 3  (0.6%) p1 = 1
p2 = 0.01
p3 = 0.1
Total 33 (8.4%) 4 (6.7%) 20 (37.7%) 57 (11.3%) p1 = 0.8
p2 = 0.001
p3 = 0.001
Total of clinically 30 (7.7%) 4 (6.7%) 15 (28.3%) 49 (9.7%) p1 = 1
significant p2 = 0.001
patients p3 = 0.01
*Indicates clinically significant, p1 –  comparison of β-thalassaemia major vs. β-thalassaemia intermedia, p2 –  comparison of β-thalassaemia
major vs. sickle cell-β-thalassaemia, p3 –  comparison of β-thalassaemia intermedia vs. sickle cell-β-thalassaemia, p < 0.05 is significant, p < 0.01
is highly significant
Table III. Frequency of red blood cell autoantibodies in β-thalassaemia patients
Alloantibody β-Thalassaemia  β-Thalassaemia  Sickle cell-β Total Value
major (n = 389) intermedia (n = 59) thalassaemia (n = 53) (n = 501) of p
IgG 99 (25.4%) 4 (6.7%) 8 (15%) 111 (22.1%) p1 = 0.005
p2 = 0.23
p3 = 0.23
IgM 27 (6.9%) 1 (1.6%) 6 (11.3%) 34 (6.8%) p1 = 0.23
p2 = 0.16
p3 = 0.06
Total 126 (32.3%) 5 (8.4%) 14 (26.4%) 145 (28.9%) p1 = 0.001
p2 = 0.6
p3 = 0.04
Ig – immunoglobulin, p1 – comparison  of  β-thalassaemia major vs. β-thalassaemia intermedia, p2 –  comparison of β-thalassaemia major vs.
sickle cell-β-thalassaemia, p3 –  comparison of β-thalassaemia intermedia vs. sickle cell-β-thalassaemia, p < 0.05 is significant, p < 0.01 is highly
significant
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was 22% and 30% respectively. The higher
alloimmunization rate in these two studies was
probably due to the heterogeneity of the populations
living in Greece and Kuwait and mismatched RBC
phenotypes between donors and recipients.
Also, other studies by Sylvia et al. [12] and Gader
et al. [13] found a high alloimmunization rate of
20.8% and 22.06% among Asians and in Saudi
Arabia because the majority of patients received
multi-ethnic blood.
In the current study anti-K (Kell system) was
seen most frequently, followed by anti-E and 
anti-C (Rhesus system), which are all potentially
haemolytic antibodies. All of our patients received
compatible blood for ABO, Rh D.
In an Italian study [14] alloantibodies were
confined to the common antigens of the Kell,
Rhesus and Kidd systems. This is similar to our
study. Also, in studies from Iran and Kuwait, Karimi
et al. [9] and Ameen et al. [6] found that the most
common alloantibodies were anti-Rh C, E and D.
Meanwhile, several studies have shown that 
anti-E antibodies were the most prevalent
alloantibodies among transfusion-dependent
thalassaemia patients [7, 8, 12]. Spanos et al. [15]
demonstrated that for prevention of alloim  -
munization, transfusion of blood matched for Rh
and K antigens resulted in a significant difference
in the alloimmunization rate.
The factors for alloimmunization are complex
and involve at least 3 main contributing elements:
the RBC antigenic difference between the blood
donor and the recipient, the recipient’s immune
status, and the immunomodulatory effect of the
allogenic blood transfusion on the recipient’s
immune system [12]. A low rate of alloimmunization
may be expected when there is homogeneity of
RBC antigens between the blood providers and
recipients [16]. Other factors beyond the antigenic
discrepancy, in particular the immune system, are
undoubtedly involved. An overall normal CD4 : CD8
ratio was shown in thalassaemia patients
transfused with post-storage leukocyte-depleted
blood [17]. However, a marked absolute
lymphocytosis mostly due to an increase in 
B lymphocytes predominantly in splenectomized
patients was reported with the use of both non-
leukoreduced and leukoreduced blood [18]. The
lymphocytosis is accompanied by an increase in
serum immunoglobulins, immune complexes, and
cells bearing surface immunoglobulins which are
the result of the immunomodulatory effect of blood
elements, absence of spleen and recipient immune
status [19, 20]. The majority of patients in the
present study had long-term exposure to non-
leukodepleted blood.
In this study the incidence of autoantibodies was
28.8%. Our data were similar to an Asian study
where 25% of their thalassaemia patients develop  -
ed autoantibodies [12]. Also a Kuwait study
observed that 11% of their patients developed
autoantibodies [6]. 
However, a study in Iran found that the rate of
autoantibodies was 1.4% [9]. Other studies in Hong
Kong [7] and Malaysia [8] reported that only one
patient developed autoantibodies.
The pathogenesis of erythrocyte autoantibody
formation following transfusion is not well
understood. However, clinical evidence of auto  -
immune haemolytic anaemia has been seen with
high amounts of RBC-associated IgG [21]. It was
Items With splenectomy Without splenectomy Value
(n = 232) (n = 269) of p
Alloantibody
β-Thalassaemia major 30 (13%) – 0.001
β-Thalassaemia intermedia 2 (0.8%) 3 (1.1%) 1
Sickle cell-β-thalassaemia 3 (1.2%) 19 (7%) 0.003
Total 35 (15%) 22 (8.1%) 0.03
Autoantibody
β-Thalassaemia major 123 (53%) – 0.001
β-Thalassaemia intermedia 8 (3.4%) 1 (0.3%) 0.01
Sickle cell-β-thalassaemia 9 (3.9%) 4 (1.5%) 0.1
Total 140 (60.3%) 5 (1.8%) 0.001
Table IV. Relationship of splenectomy with alloantibodies and autoantibodies in β-thalassaemia patients
p < 0.05 is significant, p < 0.01 is highly significant
Item Alloantibodies Autoantibodies
(Value of p)( V alue of p)
Number of transfused  0.5 0.9
packed red cells  
[units/year]
Age at start of  0.3 0.5
transfusion [year]
Table V. Relationship of red cell alloantibodies and
autoantibodies with number of transfused packed
red cells and age at start of transfusion
Value of p > 0.5 is not significant
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also suggested that alloantibody binding to the
RBCs could lead to conformational changes of the
antigenic epitope that ultimately stimulates
production of autoantibodies [22]. It is possible that
certain people are genetic responders who have an
increased tendency to develop RBC autoantibodies
and the tendency toward autoantibody formation
could reflect an overall dysfunction of the immune
system [23].
In this study there was a significant association of
splenectomy with alloimmunization and auto  -
antibodies (p= 0.03, 0.001 respectively). In agreement
with our study, Singer et al. and Sylvia et al. observed
that Asian patients with splenectomy had a higher
rate of alloimmunization compared with patients who
did not have splenectomy (p = 0.06).
Also our results were supported by Wiener et al.,
[24] who revealed that significant elevations in RBC-
bound IgG were seen in thalassaemia patients and
it was more abundant in splenectomized than non-
splenectomized subjects. They found that the
absence of a spleen may further enhance the
immune response to the infused foreign antigens
which are not effectively filtered. In contrast, Noor
Haslina et al. [8, 21] reported that in Malaysia
despite a higher rate of patients with splenectomy
none of them had alloantibodies and only one
patient had autoantibodies. 
In the present study there was no association
between alloantibodies, autoantibodies and age at
start of transfusion. Similarly, in Malaysian studies
Noor Haslina [8, 21] found that there was no
association between alloantibodies, autoantibodies
and age at start of transfusion (p = 0.5, p = 0.8
respectively).
In our study there was a significant association
between groups of β-thalassaemia patients (β-thalas  -
saemia major vs. sickle cell-β-thalassaemia; 
β-thalassaemia intermedia vs. sickle cell-β-thalas  -
saemia) regarding allo- antibodies and also 
(β-thalassaemia major vs. β-thalassaemia
intermedia; β-thalassaemia intermedia vs. sickle 
cell-β-thalassaemia) regarding autoantibodies. 
A vulnerable immune status of the recipient may
predispose to an altered or increased immune
response to various antigens. This aspect of immune
status has never been explored in our patients, and
needs to be looked into. This agrees with Fluit et al.
[25] who found that some antigen-negative patients
may not produce antibodies at all or may form only
one antibody despite exposure to antigen-positive
cells. Other patients may have serological findings
of a clinically significant alloantibody without
evidence of a haemolytic transfusion reaction, and
this agrees also with Sylvia et al. who reported that
with the growing knowledge base of the immune
effects of current blood transfusion and limited data
on immune status of thalassaemia patients, a large
study addressing the complex interaction of these
factors is needed.
In conclusion, alloimmunization to minor erythro  -
cyte antigens and erythrocyte autoantibodies of
variable clinical significance are frequent findings
in transfusion-dependent β-thalassaemia patients.
The overall frequency of alloantibody and auto  -
antibody formation in our patients is 11.3% and 28.8%
respectively. The most common alloantibodies 
are anti-K (Kell system), anti-E and anti-C (Rhesus
system). There is a significant association between
absence of the spleen and the presence of alloim  -
munization and autoantibody formation. The
difference in the RBC antigen profile between
donors and recipients together with splenectomy
in this study likely contributes to these phenomena.
We recommend obtaining an RBC antigen
phenotype for all thalassaemia patients who are
started on transfusions and providing universal
leukodepleted blood matched for antigens of the
ABO, Kell and Rh system. Recruitment of Egyptian
blood bank donors can increase the availability of
compatible blood for beta thalassaemia patients.
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